Novo Nordisk will present 34 abstracts at the upcoming 84th Scientific Sessions of the American Diabetes Association, focusing on their portfolio. The trials with semaglutide will assess benefits in diabetes, obesity, and cardiovascular disease. The data reflects the need for medicines that address multiple aspects of these interconnected conditions. Novo Nordisk aims to develop treatments for common comorbidities of diabetes and obesity, such as kidney and cardiovascular diseases. Abstracts cover a range of topics including the effectiveness of semaglutide in diabetes management, real-world impact of treatments, and the potential benefits of new insulin therapies. All abstracts will be published on the Diabetes® website.
Source link
Novo Nordisk presents key findings from semaglutide trials at ADA scientific sessions 2024
